[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615794":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":31,"locations":40,"responsibleParty":70,"collaborators":18,"id":73,"slug":18,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":18,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":18,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":43,"whyStopped":18,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Jinling Hospital, China","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental arm","EXPERIMENTAL","Participants received semaglutide as a subcutaneous injection (dosage form) at a dose of 0.25 mg (dosage) once weekly (frequency) for 28 days (duration).",[13],"Drug: GLP-1 Receptor Agonists",{"label":15,"type":16,"description":17,"interventionNames":18},"Control arm","NO_INTERVENTION","received appearance-matched placebo plus standard care, no additional semaglutide intervention therapy",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","GLP-1 Receptor Agonists","GLP-1 receptor agonists (semaglutide) are medications that mimic the action of the native human hormone glucagon-like peptide-1 (GLP-1). The recommended dosage is 0.25 mg administered subcutaneously once weekly.",[9],[26],"GLP-1RAs",[28],{"name":29,"affiliation":5,"role":30},"Xinying Wang, MD","PRINCIPAL_INVESTIGATOR",[32,37],{"name":33,"role":34,"phone":35,"phoneExt":18,"email":36},"Xin Qi, MD","CONTACT","+86 18088680475","qixin199604@126.com",{"name":29,"role":34,"phone":38,"phoneExt":18,"email":39},"+86 13913028866","wangxinying@nju.edu.cn",[41,56],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":45,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Jinling Hospital","RECRUITING","Nanjing","China","210002",{"type":48,"coordinates":49},"Point",[50,51],118.77778,32.06167,{"lat":51,"lon":50},[54],{"name":55,"role":34,"phone":35,"phoneExt":18,"email":36},"Xin Qi",{"facility":42,"status":43,"city":57,"state":45,"zip":46,"country":45,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"Nanning",{"type":48,"coordinates":59},[60,61],108.31667,22.81667,{"lat":61,"lon":60},[64,66,67,68],{"name":65,"role":34,"phone":38,"phoneExt":18,"email":39},"Xingying Wang, MD",{"name":33,"role":34,"phone":35,"phoneExt":18,"email":36},{"name":29,"role":30,"phone":18,"phoneExt":18,"email":18},{"name":33,"role":69,"phone":18,"phoneExt":18,"email":18},"SUB_INVESTIGATOR",{"type":30,"investigatorFullName":71,"investigatorTitle":72,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Wang Xinying","Prof","100615794",false,"NCT07297238","Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.","Therapeutic Efficacy of GLP-1 on Intestinal Barrier Function in Patients With Short Bowel Syndrome and Intestinal Failure: A Preliminary Randomized Controlled Trial","Inclusion Criteria:\n\n* Participants voluntarily provided written informed consent for this trial;\n* Aged 18 to 80 years, inclusive, regardless of gender;\n* With stable vital signs;\n* Diagnosis of SBS-IF, confirmed by existing medical\u002Fsurgical records, receiving parenteral nutrition (PN) due to surgical resection of the small intestine (\\\u003C200 cm from the duodenojejunal flexure), and meeting one of the following criteria:\n\n  * Colon continuity maintained without jejunal\u002Fileal stoma (Type II or III);\n\n    * Presence of a jejunostomy or ileostomy (Type I);\n* Expected requirement of PN for more than 4 weeks, with an average PN caloric intake ≥80%;\n* Ability to comply with the medication dosing and visit schedule;\n* Capacity to accurately describe symptoms, absence of severe infections or respiratory insufficiency, and willingness to cooperate proactively;\n* No history of allergic diseases, non-allergic constitution, and no hypersensitivity to any component of semaglutide injection;\n* No history of drug abuse;\n* Not pregnant or lactating; no pregnancy plans within one month after the trial (applies to both female and male participants);\n* No participation in any other drug trials (including the investigational product in this study) within three months prior to enrollment.\n\nExclusion Criteria:\n\n* Individuals who do not meet the inclusion criteria or are deemed ineligible by the investigator;\n* Poor general condition, inability to accurately describe symptoms, presence of severe infection, respiratory insufficiency, or other conditions that may hinder active cooperation;\n* History of allergic diseases, allergic constitution, or hypersensitivity to drugs structurally related to the investigational product;\n* Patients with malignancy at any site;\n* Those with psychiatric disorders, inability to cooperate, or impaired consciousness;\n* Patients with contraindications to the investigational drug (including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2);\n* Immunodeficiency, or current use of immunosuppressants or corticosteroids;\n* Immediate family members of the sponsor, investigator, or study staff directly involved in the trial;\n* Any other condition considered by the investigator as grounds for exclusion.","ALL","18 Years","80 Years",{"count":83,"type":84},20,"ESTIMATED","INTERVENTIONAL",[87],"NA","Eligible patients were randomized into two groups: the GLP-1 group and the control group. The control group received a placebo along with standard care, without any additional GLP-1-based intervention. The GLP-1 group, in addition to standard care, received a subcutaneous injection of a GLP-1 analog (semaglutide injection) strictly according to the drug manufacturer's instructions. The initial dose of semaglutide was 0.25 mg once weekly. Treatment was continued over a 28-days period. Primary and secondary outcomes will be collected.",[90,91],"Short Bowel Syndrome (SBS)","Intestinal Failure",[93,94,95,96],"GLP-1","short bowel syndrome","intestinal failure","Intestinal Barrier Function","2026-05-27",{"date":99,"type":100},"2026-05-28","ACTUAL",{"date":102,"type":100},"2026-01-24",{"date":104,"type":84},"2026-06-30",{"name":5,"class":6},2]